A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Trial Profile

A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs ARGX 110 (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors argenx
  • Most Recent Events

    • 02 May 2017 According to an argenx media release, an interim data expected by the end of 2017.
    • 15 Dec 2016 According to an argenx media release, top-line data from the dose escalation phase I portion are expected in about 18 months.
    • 15 Dec 2016 According to an argenx media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top